vs
HERON THERAPEUTICS, INC.（HRTX）与REDWOOD TRUST INC（RWT）财务数据对比。点击上方公司名可切换其他公司
HERON THERAPEUTICS, INC.的季度营收约是REDWOOD TRUST INC的1.6倍（$40.6M vs $25.9M），REDWOOD TRUST INC净利率更高（77.2% vs -7.3%，领先84.5%），HERON THERAPEUTICS, INC.同比增速更快（-0.5% vs -6.1%），过去两年HERON THERAPEUTICS, INC.的营收复合增速更高（8.2% vs -41.0%）
安提贝制药是一家总部位于多伦多的制药企业，由曾参与创立全球首个气态介质药物开发企业NicOx的约翰·L·华莱士创立于2009年。该企业专注于依托气态介质技术研发缓解疼痛与炎症的药物，2013年在多伦多风险交易所挂牌，2015年收购再生医学领域经销商Citagenix，2020年11月转板多伦多证券交易所。
Redwood Trust Inc是总部位于美国的专业房地产投资信托公司，主营住宅与商业抵押贷款、抵押贷款支持证券及房地产信贷类资产的投资管理，核心业务覆盖住宅抵押贷款发放、商业地产信贷和投资服务，客户以机构投资者和房地产市场参与者为主。
HRTX vs RWT — 直观对比
营收规模更大
HRTX
是对方的1.6倍
$25.9M
营收增速更快
HRTX
高出5.6%
-6.1%
净利率更高
RWT
高出84.5%
-7.3%
两年增速更快
HRTX
近两年复合增速
-41.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $40.6M | $25.9M |
| 净利润 | $-3.0M | $20.0M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 0.1% | — |
| 净利率 | -7.3% | 77.2% |
| 营收同比 | -0.5% | -6.1% |
| 净利润同比 | -180.6% | 402.6% |
| 每股收益（稀释后） | $-0.01 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HRTXRWT
| Q4 25 | $40.6M | $25.9M | ||
| Q3 25 | $38.2M | $15.0M | ||
| Q2 25 | $37.2M | $13.8M | ||
| Q1 25 | $38.9M | $27.9M | ||
| Q4 24 | $40.8M | $27.6M | ||
| Q3 24 | $32.8M | $25.5M | ||
| Q2 24 | $36.0M | $67.4M | ||
| Q1 24 | $34.7M | $74.5M |
净利润HRTXRWT
| Q4 25 | $-3.0M | $20.0M | ||
| Q3 25 | $-17.5M | $-7.7M | ||
| Q2 25 | $-2.4M | $-98.5M | ||
| Q1 25 | $2.6M | $16.1M | ||
| Q4 24 | $3.7M | $-6.6M | ||
| Q3 24 | $-4.8M | $14.8M | ||
| Q2 24 | $-9.2M | $15.5M | ||
| Q1 24 | $-3.2M | $30.3M |
毛利率HRTXRWT
| Q4 25 | 72.6% | — | ||
| Q3 25 | 68.8% | — | ||
| Q2 25 | 73.5% | — | ||
| Q1 25 | 78.3% | — | ||
| Q4 24 | 74.9% | — | ||
| Q3 24 | 71.2% | — | ||
| Q2 24 | 70.8% | — | ||
| Q1 24 | 75.6% | — |
营业利润率HRTXRWT
| Q4 25 | 0.1% | — | ||
| Q3 25 | -10.7% | -9.0% | ||
| Q2 25 | -4.4% | -679.0% | ||
| Q1 25 | 8.1% | 80.2% | ||
| Q4 24 | 10.2% | -1.3% | ||
| Q3 24 | -13.6% | 86.1% | ||
| Q2 24 | -17.9% | 30.3% | ||
| Q1 24 | -13.8% | 41.3% |
净利率HRTXRWT
| Q4 25 | -7.3% | 77.2% | ||
| Q3 25 | -45.8% | -51.4% | ||
| Q2 25 | -6.4% | -712.0% | ||
| Q1 25 | 6.8% | 57.8% | ||
| Q4 24 | 9.0% | -24.0% | ||
| Q3 24 | -14.8% | 58.1% | ||
| Q2 24 | -25.6% | 23.0% | ||
| Q1 24 | -9.1% | 40.6% |
每股收益（稀释后）HRTXRWT
| Q4 25 | $-0.01 | $0.11 | ||
| Q3 25 | $-0.10 | $-0.08 | ||
| Q2 25 | $-0.02 | $-0.76 | ||
| Q1 25 | $0.01 | $0.10 | ||
| Q4 24 | $0.02 | $-0.08 | ||
| Q3 24 | $-0.03 | $0.09 | ||
| Q2 24 | $-0.06 | $0.10 | ||
| Q1 24 | $-0.02 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.6M | $255.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $14.3M | $982.6M |
| 总资产 | $255.9M | $23.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HRTXRWT
| Q4 25 | $28.6M | $255.7M | ||
| Q3 25 | $43.1M | $226.3M | ||
| Q2 25 | $16.5M | $302.0M | ||
| Q1 25 | $19.3M | $259.9M | ||
| Q4 24 | $25.8M | $245.2M | ||
| Q3 24 | $25.7M | $253.7M | ||
| Q2 24 | $18.4M | $275.6M | ||
| Q1 24 | $20.4M | $275.4M |
总债务HRTXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.7B |
股东权益HRTXRWT
| Q4 25 | $14.3M | $982.6M | ||
| Q3 25 | $14.9M | $999.0M | ||
| Q2 25 | $-27.3M | $1.1B | ||
| Q1 25 | $-28.5M | $1.2B | ||
| Q4 24 | $-33.7M | $1.2B | ||
| Q3 24 | $-40.0M | $1.2B | ||
| Q2 24 | $-37.9M | $1.2B | ||
| Q1 24 | $-33.8M | $1.2B |
总资产HRTXRWT
| Q4 25 | $255.9M | $23.7B | ||
| Q3 25 | $248.9M | $22.6B | ||
| Q2 25 | $232.1M | $21.3B | ||
| Q1 25 | $235.8M | $19.9B | ||
| Q4 24 | $233.1M | $18.3B | ||
| Q3 24 | $220.8M | $18.4B | ||
| Q2 24 | $218.1M | $16.5B | ||
| Q1 24 | $217.9M | $15.1B |
负债/权益比HRTXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-9.2M | $-10.1B |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | -504.15× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流HRTXRWT
| Q4 25 | $-9.2M | $-10.1B | ||
| Q3 25 | $1.3M | $-2.7B | ||
| Q2 25 | $-10.9M | $-2.1B | ||
| Q1 25 | $-8.9M | $-2.0B | ||
| Q4 24 | $-11.8M | $-5.9B | ||
| Q3 24 | $3.4M | $-2.1B | ||
| Q2 24 | $-4.6M | $-2.0B | ||
| Q1 24 | $-9.5M | $-954.2M |
自由现金流HRTXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-11.1M | — | ||
| Q1 25 | $-9.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率HRTXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -29.8% | — | ||
| Q1 25 | -23.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 9.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度HRTXRWT
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率HRTXRWT
| Q4 25 | — | -504.15× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -3.37× | -120.92× | ||
| Q4 24 | -3.22× | — | ||
| Q3 24 | — | -140.86× | ||
| Q2 24 | — | -126.56× | ||
| Q1 24 | — | -31.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HRTX
| CINVANTI | $22.9M | 56% |
| ZYNRELEF | $12.5M | 31% |
| Aponvie | $3.8M | 9% |
| SUSTOL | $1.3M | 3% |
RWT
暂无分部数据
